Trends in acute ischemic stroke trials through the 20th century

Stroke

Volumn 32, Issue 6, 2001, Pages 1349-1359

  Kidwell, Chelsea S ^a   Liebeskind, David S ^b   Starkman, Sidney ^a   Saver, Jeffrey L ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cerebral ischemia; Clinical trials; Stroke management; Stroke, acute; Stroke, ischemic

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ARTICLE; BLOOD RHEOLOGY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; NEUROPROTECTION; PRIORITY JOURNAL; QUALITY CONTROL; STROKE;

EID: 0034983276     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.32.6.1349     Document Type: Article

References (45)

1. Clinical trial design for cerebrovascular disorders
2. Tissue plasminogen activator for acute ischemic stroke
3. The Ottawa Stroke Trials Registry Collaborative Group and the development of the Ottawa Stroke Trials Registry (OSTR)
4. Recently developed neuroprotective therapies for acute stroke: A qualitative systematic review of clinical trials
5. Measurements of acute cerebral infarction: A clinical examination scale
6. Functional evaluation: The barthel index
7. Incorporating variations in the quality of individual randomized thais into metaanalysis
8. Neuroprotective therapy for acute ischemic stroke: Quality assessment of controlled trials
9. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
10. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
11. Tissue plasminogen activator for acute ischemic stroke
12. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial: Prolyse in acute cerebral thromboembolism
13. Low-molecular-weight heparin for the treatment of acute ischemic stroke
14. Improving the quality of reporting of randomized controlled trials: The CONSORT statement
15. Quality of full and final publications reporting acute stroke trials: A systematic review
16. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer: A lost opportunity for meta-analysis
17. Full publication of results initially presented in abstracts: A meta-analysis
18. Thirty years of medical research council randomized trials in solid tumours
19. What questions can large, simple trials answer?
20. Statistical power, sample size, and their reporting in randomized controlled trials
21. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials
22. Reports of randomized trials in acute stroke, 1955 to 1995: What proportions were commercially sponsored?
23. Empiric evidence of publication bias affecting acute stroke clinical trials
24. Publication bias in clinical research
25. Factors influencing publication of research results: Follow-up of applications submitted to two institutional review boards
26. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke
27. PET imaging of cerebral peffusion and oxygen consumption in acute ischaemic stroke: Relation to outcome
28. Factors determining the therapeutic window for stroke
29. Duration of neuroprotective treatment for ischemic stroke
30. Outcome measures in acute stroke trials: A systematic review and some recommendations to improve practice
31. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke
32. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
33. The Cochrane Collaboration Stroke Review Group: Meeting the need for systematic reviews in stroke care
34. Interpretation of IST and CAST stroke trials: International Stroke Trial/Chinese Acute Stroke Trial
35. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
36. Cerestat and other NMDA antagonists in ischemic stroke
37. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke
38. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials
39. Meta-analysis: Bias in location and selection of studies
40. Completeness of reporting of trials published in languages other than English: Implications for conduct and reporting of systematic reviews
41. An amnesty for unpublished trials